FDA/CDC

Lymphoma risk prompts FDA recall of Allergan’s textured breast implants


 

Pages

Recommended Reading

CAR T-cell therapy bb2121 performs well in phase 1 trial of refractory multiple myeloma
AVAHO
Lenalidomide may reduce risk of progression from SMM to MM
AVAHO
Daratumumab regimen shows benefit in transplant-ineligible myeloma
AVAHO
Chemo-free Smart Start regimen looks promising in poor-prognosis DLBCL
AVAHO
R2 appears active in high-risk FL and MZL
AVAHO
Partners in Oncology Care: Coordinated Follicular Lymphoma Management (FULL)
AVAHO
Cell count ratios appear to predict thromboembolism in lymphoma
AVAHO
CNS-directed therapy appears more effective for synDLBCL
AVAHO
R2-CHOP doesn’t improve survival in DLBCL
AVAHO
SC daratumumab deemed feasible for every multiple myeloma patient
AVAHO